Roche is paying up to $1.53 billion to license an experimental antibody from China’s Simcere — a bet on a next-generation format for treating autoimmune disease.
The asset, SIM0660, is a tri-specific antibody: a single molecule engineered to grab three targets at once, designed to provide broad coverage across B-cell-mediated diseases. B cells are central drivers of many autoimmune conditions, and hitting them from multiple angles could, in theory, be more effective than single-target drugs. Notably, SIM0660 is still a preclinical asset — making the price tag a statement of confidence in the approach.
Why it matters
Autoimmune disease has become one of the hottest areas in pharma, with companies racing to develop B-cell-targeting therapies — from CAR-T cell therapies to bispecific and now tri-specific antibodies. Roche’s willingness to pay more than a billion dollars for a drug that hasn’t yet reached human trials reflects how much the industry believes deep B-cell targeting could reshape autoimmune treatment. It also continues a wave of Western pharma companies licensing early-stage innovation from Chinese biotechs. As a preclinical deal, the real test — human safety and efficacy — is still years away.